CTIX News $CTIX
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
Marketwire - Tue Sep 02, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. Barry Schechter M.D. F.A.A.O. to the Cellceutix Board of Directors, effective October 1st, 2014. Dr. Schechter, a Principal and the Director of the Department of Cornea and External Disease at Florida Eye Microsurgical Institute, brings years of experience to Cellceutix through his specialization in ocular pathology and diseases, including infections.
Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Marketwire - Tue Aug 19, 7:31AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, has announced the completion of enrollment in its Phase 2b trial comparing Brilacidin(TM) to daptomycin (Cubicin(R)) in patients with acute bacterial skin and skin structure infections (ABSSSI). Overall, 215 patients were randomized to one of three dosing regimens of Brilacidin (single dose 0.6mg/kg; single-dose 0.8mg/kg; 1.2mg/kg over 3 days) or 7 days of once daily daptomycin.
Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis
Marketwire - Mon Aug 11, 6:00AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that the Company has just received the final toxicology report for Brilacidin-OM. Cellceutix is developing Brilacidin-OM as a new treatment for oral mucositis, a common and often debilitating inflammation and ulceration that occurs in the mouth as a side effect of certain cancer treatments, including chemotherapy and radiation therapy.
Cellceutix Anti-Psoriasis Drug Prurisol Meets Primary Endpoint of Clinical Trial
Marketwire - Fri Aug 08, 5:03AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that it has just received notice that the data from its Phase 1 trial of the Company's anti-psoriasis drug candidate Prurisol(TM) for the conversion of Prurisol to abacavir indicated "the areas are within passing Bioequivalency limits." Cellceutix believes it has met the primary endpoints and objectives of the study. Cellceutix is developing Prurisol(TM) under guidance from the U.S. Food and Drug Administration that a 505(b)(2) designation is an acceptable pathway to expedite development of the compound for treating psoriasis.
Cellceutix Believes Brilacidin on Track to Help U.S. Avoid Falling Into Post-Antibiotic Era; Completion of Enrollment in Phase 2b Trial for Acute Bacterial Skin and Skin Structure Infections Expected This Month
Marketwire - Mon Aug 04, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to inform shareholders that it expects completion of enrollment in its Phase 2b trial of Brilacidin(TM) for Acute Bacterial Skin and Skin Structure Infections ("ABSSSI" , by the end of this month. Brilacidin is Cellceutix's lead antibiotic drug candidate in a new class of compounds called defensin-mimetics. Brilacidin is designed to act as a synthetic version of the naturally occurring defensins, peptides with antimicrobial activities that have been part of the innate immune response throughout evolution. By disrupting the structural integrity of bacteria, as opposed to interfering via a biochemical approach as most classes of antibiotics do, Brilacidin has an intrinsic ability to avoid the development of resistance.
Plague - Pipeline Review, H1 2014
M2 - Wed Jul 30, 2:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xgdb3j/plague_pipeline) has announced the addition of the "Plague - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Plague, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plague and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Plague - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Plague and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Plague products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Takeda Pharmaceutical - Summit Corporation - Mucosis - iBio - Cellceutix Corporation For more information visit http://www.researchandmarkets.com/research/xg...e_pipeline
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g486rc/methicillinsuscep) has announced the addition of the "Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Dainippon Sumitomo Pharma Co., Ltd. - Immtech Pharmaceuticals, Inc. - Cellceutix Corporation - Lytix Biopharma AS - PharmaIN Corporation - ImmuVen, Inc. - Arsanis Biosciences GmbH For more information visit http://www.researchandmarkets.com/research/g4...llinsuscep
Cellceutix Announces Breakthrough in the Formulation of Its Novel Antibiotic Brilacidin(TM), Plans Studies to Treat Diabetic Foot Ulcers
Marketwire - Mon Jul 14, 6:00AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that a significant breakthrough has been made in the formulation of Brilacidin(TM), Cellceutix's lead antibiotic in its portfolio of novel compounds called defensin mimetics. Previously, Brilacidin was stored in a refrigerated state. Cellceutix has stabilized the formulation of Brilacidin so that it is now stable at room temperature. This positions the Company to move forward with the immediate development of Brilacidin for the treatment of infected diabetic foot ulcers. Ophthalmic and otitic formulations will soon follow for ophthalmic and otitis media indications.
Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant
Marketwire - Mon Jun 23, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that a research collaboration with Fox Chase Chemical Diversity Center ("FCCDC" (http://www.fc-cdci.com) has led to the award of a Phase 2B Small Business Innovation Research (SBIR) grant to FCCDC from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institute of Health (NIH).
Autism - Pipeline Review, H1 2014 - 20 Companies & 42 Drug Profiles
M2 - Fri Jun 20, 2:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltzhjv/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - Merz Pharma GmbH & Co. KgaA - Teva Pharmaceutical Industries Limited - Avanir Pharmaceuticals, Inc. - Snowdon Inc. - Curemark, LLC - Coronado Biosciences, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Cellceutix Corporation - Heptares Therapeutics Ltd. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Naurex, Inc. - Nectid, Inc. - Mnemosyne Pharmaceuticals, Inc. - BioCrea GmbH - Saniona AB Drug Profiles - CM-AT - lurasidone hydrochloride - aripiprazole - cycloserine - fluoxetine - oxytocin - oxytocin - memantine hydrochloride - TSO - pioglitazone hydrochloride - oxytocin - oxytocin - (dextromethorphan hydrobromide quinidine sulfate) - oxytocin - oxytocin - RG-7314 - fluoxetine - fluoxetine - argipressin tannate - NU-211-01 NC-215-01 - Autologous Hematopoietic Stem Cells - glatiramer acetate - ITI-007 - Stem Cell Therapy for Central Nervous System Disorders - KM-391 - Program For Neurological Disorders - STX-110 - CN-2097 - acamprosate calcium - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome For more information visit http://www.researchandmarkets.com/research/lt...m_pipeline
Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering Eighth Cohort
Marketwire - Mon Jun 16, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that the safety committee overseeing the Phase 1 clinical trial evaluating Cellceutix's lead anti-cancer drug Kevetrin for solid tumors being conducted at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center has approved dosing for the eighth cohort. The dosing was been increased approximately 33 percent from the seventh cohort to 215 mg/m2. Enrollment for the eighth cohort is expected to commence shortly.
Cellceutix Comments on Positive FDA Advisory Vote for Dalbavancin and Tedizolid
Marketwire - Tue Apr 01, 7:04AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" is pleased to comment to its shareholders on yesterday's exciting regulatory developments and how it impacts Cellceutix's drug, Brilacidin.
Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI
Marketwire - Mon Mar 31, 8:25AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to provide shareholders an update on the status of the Company's clinical trial of its novel antibiotic Brilacidin as a treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). One month into the study, the trial has completed enrollment of approximately 20 percent of the total patients scheduled in the protocol.
Cellceutix Initiates Clinical Trial of Prurisol as New Treatment for Psoriasis
Marketwire - Tue Mar 25, 5:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the initiation of the Company's clinical trial of its oral, small molecule drug candidate Prurisol(TM) for the treatment of psoriasis. The Prurisol(TM) tablets have been delivered to the clinical site in Miami, Florida and screening of subjects can now begin with the first dosing expected in the coming days.
Cellceutix to Initiate Psoriasis Clinical Trial
Marketwire - Fri Mar 21, 5:00AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the U.S. Food and Drug Administration's ("FDA" 30-day waiting period pertaining to the Company's Investigational New Drug Application ("IND" for Prurisol(TM) has now passed. Cellceutix is moving towards the commencement of clinical trials of Prurisol(TM) as a new drug candidate for the treatment of psoriasis.
Seventh Cohort Underway in Cellceutix Clinical Trial of Kevetrin for Solid Tumors
Marketwire - Wed Mar 19, 7:42AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the seventh cohort is now in progress in the Company's ongoing Phase 1 clinical trial of Kevetrin(TM), Cellceutix's novel anti-cancer drug candidate.
Cellceutix Reports 14 Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Patients Treated in Phase 2b Clinical Trial
Marketwire - Mon Mar 10, 5:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that through March 7 a total of 14 patients have been treated in the Company's Phase 2b clinical (7% of the 200 patients to be treated). The multi-center study is evaluating the safety and efficacy of Brilacidin as a novel antibiotic drug candidate as compared to daptomycin for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Patients are receiving one of three different dosing regimens of Brilacidin (one of two single-dose regimens or one 3-day regimen) or a 7-day regimen of daptomycin. Cellceutix is pleased with the initial enrollment pace and believes that it will continue to escalate as the trial moves forward.
Cellceutix Expands to Gram-Negative Bacterial Infections
Marketwire - Wed Mar 05, 5:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to inform shareholders that several preclinical investigations are underway with several lead compounds in animal models of Gram-negative bacterial infections. The Company is focusing this research on some of the most difficult to treat multi-drug resistant or "pandrug-resistant" bacterium where there is a significant and growing medical need for new therapies.
Cellceutix Enrolls First Patients in Phase 2b ABSSSI Clinical Trial
Marketwire - Wed Feb 26, 5:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the first patients have been enrolled and treated in the Company's Phase 2b clinical trial of Brilacidin in patients with Acute Bacterial Skin and Skin Structure Infection (ABSSSI).
Cellceutix Selects Dr. Reddy's Laboratories for Formulation of Brilacidin for Ophthalmic and Otitis Infections
Marketwire - Mon Feb 24, 6:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the Company has concluded negotiations with formulation developers and selected Dr. Reddy's Custom Pharmaceutical Services (CPS), part of the Pharmaceutical Services and Active Ingredients (PSAI) business unit of Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's" , a New York Stock Exchange-listed company traded under the ticker "RDY", for the formulation of the Company's defensin mimetic drug Brilacidin for use in ophthalmic and otitis infections.
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
Marketwire - Tue Sep 02, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. Barry Schechter M.D. F.A.A.O. to the Cellceutix Board of Directors, effective October 1st, 2014. Dr. Schechter, a Principal and the Director of the Department of Cornea and External Disease at Florida Eye Microsurgical Institute, brings years of experience to Cellceutix through his specialization in ocular pathology and diseases, including infections. Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Marketwire - Tue Aug 19, 7:31AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, has announced the completion of enrollment in its Phase 2b trial comparing Brilacidin(TM) to daptomycin (Cubicin(R)) in patients with acute bacterial skin and skin structure infections (ABSSSI). Overall, 215 patients were randomized to one of three dosing regimens of Brilacidin (single dose 0.6mg/kg; single-dose 0.8mg/kg; 1.2mg/kg over 3 days) or 7 days of once daily daptomycin. Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis
Marketwire - Mon Aug 11, 6:00AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that the Company has just received the final toxicology report for Brilacidin-OM. Cellceutix is developing Brilacidin-OM as a new treatment for oral mucositis, a common and often debilitating inflammation and ulceration that occurs in the mouth as a side effect of certain cancer treatments, including chemotherapy and radiation therapy. Cellceutix Anti-Psoriasis Drug Prurisol Meets Primary Endpoint of Clinical Trial
Marketwire - Fri Aug 08, 5:03AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that it has just received notice that the data from its Phase 1 trial of the Company's anti-psoriasis drug candidate Prurisol(TM) for the conversion of Prurisol to abacavir indicated "the areas are within passing Bioequivalency limits." Cellceutix believes it has met the primary endpoints and objectives of the study. Cellceutix is developing Prurisol(TM) under guidance from the U.S. Food and Drug Administration that a 505(b)(2) designation is an acceptable pathway to expedite development of the compound for treating psoriasis. Cellceutix Believes Brilacidin on Track to Help U.S. Avoid Falling Into Post-Antibiotic Era; Completion of Enrollment in Phase 2b Trial for Acute Bacterial Skin and Skin Structure Infections Expected This Month
Marketwire - Mon Aug 04, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to inform shareholders that it expects completion of enrollment in its Phase 2b trial of Brilacidin(TM) for Acute Bacterial Skin and Skin Structure Infections ("ABSSSI" , by the end of this month. Brilacidin is Cellceutix's lead antibiotic drug candidate in a new class of compounds called defensin-mimetics. Brilacidin is designed to act as a synthetic version of the naturally occurring defensins, peptides with antimicrobial activities that have been part of the innate immune response throughout evolution. By disrupting the structural integrity of bacteria, as opposed to interfering via a biochemical approach as most classes of antibiotics do, Brilacidin has an intrinsic ability to avoid the development of resistance. Plague - Pipeline Review, H1 2014
M2 - Wed Jul 30, 2:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xgdb3j/plague_pipeline) has announced the addition of the "Plague - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Plague, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plague and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Plague - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Plague and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Plague products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Takeda Pharmaceutical - Summit Corporation - Mucosis - iBio - Cellceutix Corporation For more information visit http://www.researchandmarkets.com/research/xg...e_pipeline
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g486rc/methicillinsuscep) has announced the addition of the "Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Dainippon Sumitomo Pharma Co., Ltd. - Immtech Pharmaceuticals, Inc. - Cellceutix Corporation - Lytix Biopharma AS - PharmaIN Corporation - ImmuVen, Inc. - Arsanis Biosciences GmbH For more information visit http://www.researchandmarkets.com/research/g4...llinsuscep
Cellceutix Announces Breakthrough in the Formulation of Its Novel Antibiotic Brilacidin(TM), Plans Studies to Treat Diabetic Foot Ulcers
Marketwire - Mon Jul 14, 6:00AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that a significant breakthrough has been made in the formulation of Brilacidin(TM), Cellceutix's lead antibiotic in its portfolio of novel compounds called defensin mimetics. Previously, Brilacidin was stored in a refrigerated state. Cellceutix has stabilized the formulation of Brilacidin so that it is now stable at room temperature. This positions the Company to move forward with the immediate development of Brilacidin for the treatment of infected diabetic foot ulcers. Ophthalmic and otitic formulations will soon follow for ophthalmic and otitis media indications. Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant
Marketwire - Mon Jun 23, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that a research collaboration with Fox Chase Chemical Diversity Center ("FCCDC" (http://www.fc-cdci.com) has led to the award of a Phase 2B Small Business Innovation Research (SBIR) grant to FCCDC from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institute of Health (NIH). Autism - Pipeline Review, H1 2014 - 20 Companies & 42 Drug Profiles
M2 - Fri Jun 20, 2:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltzhjv/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - Merz Pharma GmbH & Co. KgaA - Teva Pharmaceutical Industries Limited - Avanir Pharmaceuticals, Inc. - Snowdon Inc. - Curemark, LLC - Coronado Biosciences, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Cellceutix Corporation - Heptares Therapeutics Ltd. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Naurex, Inc. - Nectid, Inc. - Mnemosyne Pharmaceuticals, Inc. - BioCrea GmbH - Saniona AB Drug Profiles - CM-AT - lurasidone hydrochloride - aripiprazole - cycloserine - fluoxetine - oxytocin - oxytocin - memantine hydrochloride - TSO - pioglitazone hydrochloride - oxytocin - oxytocin - (dextromethorphan hydrobromide quinidine sulfate) - oxytocin - oxytocin - RG-7314 - fluoxetine - fluoxetine - argipressin tannate - NU-211-01 NC-215-01 - Autologous Hematopoietic Stem Cells - glatiramer acetate - ITI-007 - Stem Cell Therapy for Central Nervous System Disorders - KM-391 - Program For Neurological Disorders - STX-110 - CN-2097 - acamprosate calcium - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome For more information visit http://www.researchandmarkets.com/research/lt...m_pipeline
Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering Eighth Cohort
Marketwire - Mon Jun 16, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that the safety committee overseeing the Phase 1 clinical trial evaluating Cellceutix's lead anti-cancer drug Kevetrin for solid tumors being conducted at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center has approved dosing for the eighth cohort. The dosing was been increased approximately 33 percent from the seventh cohort to 215 mg/m2. Enrollment for the eighth cohort is expected to commence shortly. Cellceutix Comments on Positive FDA Advisory Vote for Dalbavancin and Tedizolid
Marketwire - Tue Apr 01, 7:04AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
is pleased to comment to its shareholders on yesterday's exciting regulatory developments and how it impacts Cellceutix's drug, Brilacidin. Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI
Marketwire - Mon Mar 31, 8:25AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to provide shareholders an update on the status of the Company's clinical trial of its novel antibiotic Brilacidin as a treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). One month into the study, the trial has completed enrollment of approximately 20 percent of the total patients scheduled in the protocol. Cellceutix Initiates Clinical Trial of Prurisol as New Treatment for Psoriasis
Marketwire - Tue Mar 25, 5:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the initiation of the Company's clinical trial of its oral, small molecule drug candidate Prurisol(TM) for the treatment of psoriasis. The Prurisol(TM) tablets have been delivered to the clinical site in Miami, Florida and screening of subjects can now begin with the first dosing expected in the coming days. Cellceutix to Initiate Psoriasis Clinical Trial
Marketwire - Fri Mar 21, 5:00AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the U.S. Food and Drug Administration's ("FDA" 30-day waiting period pertaining to the Company's Investigational New Drug Application ("IND" for Prurisol(TM) has now passed. Cellceutix is moving towards the commencement of clinical trials of Prurisol(TM) as a new drug candidate for the treatment of psoriasis. Seventh Cohort Underway in Cellceutix Clinical Trial of Kevetrin for Solid Tumors
Marketwire - Wed Mar 19, 7:42AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the seventh cohort is now in progress in the Company's ongoing Phase 1 clinical trial of Kevetrin(TM), Cellceutix's novel anti-cancer drug candidate. Cellceutix Reports 14 Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Patients Treated in Phase 2b Clinical Trial
Marketwire - Mon Mar 10, 5:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that through March 7 a total of 14 patients have been treated in the Company's Phase 2b clinical (7% of the 200 patients to be treated). The multi-center study is evaluating the safety and efficacy of Brilacidin as a novel antibiotic drug candidate as compared to daptomycin for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Patients are receiving one of three different dosing regimens of Brilacidin (one of two single-dose regimens or one 3-day regimen) or a 7-day regimen of daptomycin. Cellceutix is pleased with the initial enrollment pace and believes that it will continue to escalate as the trial moves forward. Cellceutix Expands to Gram-Negative Bacterial Infections
Marketwire - Wed Mar 05, 5:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to inform shareholders that several preclinical investigations are underway with several lead compounds in animal models of Gram-negative bacterial infections. The Company is focusing this research on some of the most difficult to treat multi-drug resistant or "pandrug-resistant" bacterium where there is a significant and growing medical need for new therapies. Cellceutix Enrolls First Patients in Phase 2b ABSSSI Clinical Trial
Marketwire - Wed Feb 26, 5:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the first patients have been enrolled and treated in the Company's Phase 2b clinical trial of Brilacidin in patients with Acute Bacterial Skin and Skin Structure Infection (ABSSSI). Cellceutix Selects Dr. Reddy's Laboratories for Formulation of Brilacidin for Ophthalmic and Otitis Infections
Marketwire - Mon Feb 24, 6:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the Company has concluded negotiations with formulation developers and selected Dr. Reddy's Custom Pharmaceutical Services (CPS), part of the Pharmaceutical Services and Active Ingredients (PSAI) business unit of Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's" , a New York Stock Exchange-listed company traded under the ticker "RDY", for the formulation of the Company's defensin mimetic drug Brilacidin for use in ophthalmic and otitis infections. 
